Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820680 | 0.75 | HTR2A (0.33) | HTR6 | |
| SCHEMBL617432 | 0.75 | HTR6 (0.30) | HTR6 | |
| SCHEMBL820676 | 0.69 | HTR6 (0.34) | SIGMAR1HTR6 | |
| Hydrochloric Acid SCHEMBL7899361 | 0.67 | SIGMAR1 (0.36) | SIGMAR1HTR6 | |
| SCHEMBL29603716 | 0.66 | SIGMAR1 (0.38) | SIGMAR1HTR6 | |
| SCHEMBL28003595 | 0.66 | SIGMAR1 (0.38) | SIGMAR1HTR6 | |
| SCHEMBL29658875 | 0.66 | SIGMAR1 (0.41) | SIGMAR1HTR6 | |
| SCHEMBL668104 | 0.66 | SIGMAR1 (0.38) | SIGMAR1HTR6 | |
| SCHEMBL5597184 | 0.66 | SIGMAR1 (0.41) | SIGMAR1HTR6 | |
| SCHEMBL6909234 | 0.66 | HTR2A (0.37) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. | 2021-09-16 | — | — | US | disclosed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | disclosed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | disclosed |
| US-20050020437-A1 | Microparticulate material | MERCK PATENT GMBH (DE) | 2005-01-27 | — | — | US | disclosed |
| US-20040014917-A1 | Catalyst support, production and use thereof in the polymerization of olefins | MERCK PATENT GMBH (DE) | 2004-01-22 | — | — | US | disclosed |
| EP-0294942-B2 | Solid catalyst for polymerizing an olefin | MITSUI CHEMICALS INC (JP) | 2002-05-08 | — | — | EP | disclosed |
| US-6197985-B1 | METALLOCENE SUPPORTS; OLEFIN POLYMERIZATION CATALYSTS | MITSUI CHEMICALS INC (JP) | 2001-03-06 | — | — | US | disclosed |
| US-6063726-A | CATALYST COMPRISING SOLID COMPONENT OBTAINED BY SUPPORTING ZIRCONIUM COMPOUND ON POROUS INORGANIC OXIDE TREATED WITH HALOGENATED ALUMOXANE, ALUMOXANE | MITSUI CHEMICALS, INC. (JP) | 2000-05-16 | — | — | US | disclosed |
| US-4923833-A | Catalyst for olefin polymerization and processes for its production | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| US-4921825-A | DEPOSITING AN ALUMINOXANE ON CARRIER TRANSITION METAL COMPOUND | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4874734-A | USING SOLUTION OF ALUMINOXANE, PARTICULATE CARRIER WITH TRANSITION METAL COMPOUND, SOLVENT IN WHICH ALUMINOXANE IS INSOLUBLE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0327649-A1 | CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-16 | — | — | EP | disclosed |
| EP-0314797-A1 | OLEFIN POLYMERIZATION CATALYST AND PROCESS FOR POLYMERIZING OLEFIN | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-05-10 | — | — | EP | disclosed |
| EP-0295312-A1 | SOLID CATALYST FOR OLEFIN POLYMERIZATION AND PROCESS FOR ITS PREPARATION | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-12-21 | — | — | EP | disclosed |
| EP-0285443-A1 | Process for producing solid catalyst for polymerization of olefins | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-10-05 | — | — | EP | disclosed |
| EP-0283164-A2 | Cyclo-olefinic random copolymer, olefinic random copolymer, and process for producing cyclo-olefinic random copolymers | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-09-21 | — | — | EP | disclosed |
| EP-0279863-A1 | CATALYST FOR POLYMERIZING ALPHA-OLEFIN AND POLYMERIZATION PROCESS | MITSUI CHEMICALS, INC. (JP) | 1988-08-31 | — | — | EP | disclosed |
| EP-0279586-A2 | Finely divided aluminoxane, process for producing same and its use | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283172-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | SIGMAR1 151/4885HTR6 2080/4885 |
| US-20230137384-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | OGFR, ALOX5, PTGS1 | SIGMAR1 151/4885HTR6 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.